로딩 중…
지수 로딩 중…
MYUNGMOON PHARM CO.,LTD
017180· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩1,136+4.89%
2026-08-04
Financials
Valuation Metrics
MYUNGMOON PHARM CO.,LTD's Market Cap is ₩386B. At end of 2025 it was ₩628B. Ranked #1923 of 2,436 in KR market (top 79%), #727 of 787 on KOSPI (top 92%), #209 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 89%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 38.57B KRW | KR#1,923/2,436 Sec#209/234 |
| Revenue | 197.37B KRW | KR#1,029/2,436 Sec#62/234 |
| Net Income | 2.55B KRW | KR#1,308/2,436 Sec#91/234 |
| Total Assets | 273.93B KRW | KR#1,063/2,436 Sec#74/234 |
| Net Assets | 103.40B KRW | KR#1,370/2,436 Sec#112/234 |
| Employees | 297 | KR#788/2,436 Sec#68/234 |
| Value | ||
| P/E | 15.10x | KR#976/2,436 Sec#60/234 |
| P/B | 0.37x | KR#488/2,436 Sec#17/234 |
| PEG | 0.08x | KR#363/2,436 Sec#20/234 |
| P/S | 0.20x | KR#345/2,436 Sec#6/234 |
| EV/EBITDA | 16.34x | KR#913/2,436 Sec#53/234 |
| Profitability | ||
| ROE | 2.47% | KR#1,282/2,436 Sec#91/234 |
| ROA | 0.93% | KR#1,335/2,436 Sec#96/234 |
| Op. Margin | 4.07% | KR#1,041/2,436 Sec#82/234 |
| Revenue Growth | 4.63% | KR#1,178/2,436 Sec#110/234 |
| Earnings Growth | 179.02% | KR#275/2,436 Sec#19/234 |
| Financial Health | ||
| Debt Ratio | 264.92% | KR#2,049/2,436 Sec#215/234 |
| Total Debt | 97.00B KRW | KR#726/2,436 Sec#45/234 |
| Cash | 4.23B KRW | KR#2,058/2,436 Sec#189/234 |
| Current Ratio | 0.95x | KR#1,877/2,436 Sec#187/234 |
| Net Debt/EBITDA | 11.54x | KR#1,307/2,436 Sec#94/234 |
| Dividend | ||
| Div. Growth | 18.83% | KR#457/2,436 Sec#24/234 |
| Performance | ||
| 1Y Return | -28.60% | KR#1,561/2,436 Sec#135/234 |
| 1M Return | -10.48% | KR#1,804/2,436 Sec#170/234 |
| From 52W High | -44.72% | KR#991/2,436 Sec#78/234 |
| 1Y MDD | -45.66% | KR#733/2,436 Sec#59/234 |
| Trading | ||
| Volume | 50,708 shares | KR#1,261/2,436 Sec#121/234 |
| Foreign Own. | 2.34% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 89 KRW | KR#1,379/2,436 Sec#97/234 |
| BPS | 2,929 KRW | KR#1,828/2,436 Sec#143/234 |
Company Info
동사는 1983년 설립된 제약회사로, 2018년 제2공장을 신축하고, 2024년 종속회사 명문바이오가 GMP 인증을 획득하여 의약품 공급 및 매출 성장 기반을 마련함. 의약품부문에서 경피흡수제형 패취제와 고혈압, 당뇨, 항암제 등을 연구 및 출시하고 있으며, 서비스부문에서는 골프클럽을 운영하고 있음. 인구고령화에 따른 의약품 수요 증가와 난치성 질환 치료제 시장 성장에 대응하여 매출액의 약 2.49%를 연구 개발에 투자하고 있음. 명문제약는 1983년에 설립되었으며 경기도 화성시에 본사를 두고 있습니다.